BPC-157 vs GHK-Cu: What's the Difference

BPC-157 and GHK-Cu are two research peptides with completely different structures, origins and mechanisms: BPC-157 is a 15-amino-acid peptide derived from a gastric protein, while GHK-Cu is a tripeptide (three amino acids) bound to a copper ion, originally isolated from human plasma. They are not variants of the same compound and they don't occupy the same role in the scientific literature — they sit in separate research lines, with separate papers, and they are not interchangeable in a laboratory protocol.

What is BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic fragment derived from a protein found naturally in gastric juice. It is the most-cited peptide in the tissue-repair literature in animal models: most of the studies indexed on PubMed investigate it in rats and mice, evaluating its effect on tendon, muscle, intestinal and vascular tissue. The full molecule has 15 amino acids and is stable at room temperature for short periods, which makes it relatively straightforward to handle in the lab compared with longer peptides.

In PeptoClinic's catalogue, BPC-157 is quoted for destinations including Argentina as research material, with the corresponding batch documentation.

What is GHK-Cu

GHK-Cu (Glycyl-Histidyl-Lysine, bound to copper) is a much shorter peptide: just three amino acids — glycine, histidine, lysine — with a coordinated copper ion in its structure. It was first identified in human plasma in the 1970s, and research since then has concentrated on two main lines: skin biology (fibroblast activation, collagen remodeling) and, more recently, gene expression and cellular aging studies in in vitro models. Unlike BPC-157, which is a "free" peptide fragment, GHK-Cu depends on its bond with copper for the activity described in the papers — separating the peptide from the metal changes the molecule under study.

The Argentina page for GHK-Cu has the format and documentation details the compound ships with.

The core differences, summarized

The differences that matter to someone comparing both compounds before deciding what to request in a research order:

• Molecule size: BPC-157 has 15 amino acids; GHK-Cu has 3 plus a copper ion. These are structures of very different complexity.
• Origin of the reference compound: BPC-157 is derived from a gastric protein; GHK-Cu was identified in human plasma.
• Focus of the literature: BPC-157 is studied mainly in systemic tissue repair (tendon, intestine, vessels); GHK-Cu is studied mainly in dermal biology and gene expression models.
• Dependence on a cofactor: GHK-Cu requires the coordinated copper for the activity described in the studies; BPC-157 does not depend on a metal for its structure.
• Stability: as a longer peptide, BPC-157 typically requires more careful temperature handling than a tripeptide like GHK-Cu, though both ship lyophilized precisely to minimize that concern.

None of these points implies that one compound is "better" than the other — they are different objects of study, and which one fits a given protocol depends on what the laboratory is investigating, not on a comparison of potency.

What a laboratory report certifies for each one

PeptoClinic publishes third-party reports for its batches, all analyzed by Janoshik Analytical. The report for GHK-Cu (50 mg batch) and the report for BPC-157 — which in the analyzed lot is combined with TB-500, 5 mg of each compound out of 10 mg total — are both available for online verification on the laboratory's site. Neither report lists a purity percentage on the document itself: that's different from other compounds in the catalogue, such as retatrutide or MOTS-c, whose reports do state the exact figure.

This matters to anyone comparing suppliers: a certificate of analysis is only useful if it can be opened and checked against the laboratory that signed it. The PeptoClinic quality page explains how to read one of these documents before treating any purity number in an ad as valid.

Exclusively for laboratory research use

BPC-157 and GHK-Cu are supplied strictly for research use only (RUO): in vitro and laboratory studies. Neither compound is a medicine, a supplement or a food. Neither is approved for human or veterinary consumption, diagnosis or treatment, and none of the claims about them have been evaluated by the FDA, ANMAT or an equivalent authority. PeptoClinic is not a pharmacy or a telehealth provider, does not issue administration protocols, and does not answer inquiries oriented toward use in people.

How a batch is documented for a shipment to Argentina

Every compound in the catalogue is quoted on request: a researcher describes what their program needs — compound, purity specification, quantity — and the technical team responds with a written quote that includes the shipping route, cold-chain handling and the customs documentation needed to bring the material into Argentina as laboratory reference material. There is no published price and no shopping cart: the process is a technical inquiry, not a direct sale.

Anyone looking for either compound, or any other one in the catalogue destined for Argentina, can review the full list of compounds available for Argentina before sending an inquiry. Shipping logistics and lead-time handling are described on the shipping page.